Effects of Metformin on Metabolite Profiles and LDL Cholesterol in Patients With Type 2 Diabetes

T. Xu, S. Brandmaier, A.C. Messias, C. Herder, H.H.M. Draisma, A. Demirkan, Z. Yu, J.S. Ried, T. Haller, M. Heier, M. Campillos, G. Fobo, R. Stark, C. Holzapfel, J. Adam, S. Chi, M. Rotter, T. Panni, A.S. Quante, Y. HeC. Prehn, W. Roemisch-Margl, G. Kastenmüller, G. Willemsen, R. Pool, K. Kasa, K. Willems van Dijk, T. Hankemeier, C. Meisinger, B. Thorand, A. Ruepp, M. Hrabé de Angelis, Y. Li, H.-E. Wichmann, B. Stratmann, K. Strauch, A. Metspalu, C. Gieger, K. Suhre, J. Adamski, T. Illig, W. Rathmann, M. Roden, A. Peters, C.M. van Duijn, D.I. Boomsma, T. Meitinger, R. Wang-Sattler

Research output: Contribution to JournalArticleAcademicpeer-review


OBJECTIVE Metformin is used as a first-line oral treatment for type 2 diabetes (T2D). However, the underlying mechanism is not fully understood. Here, we aimed to comprehensively investigate the pleiotropic effects of metformin. RESEARCH DESIGN AND METHODS We analyzed both metabolomic and genomic data of the population-based KORA cohort. To evaluate the effect of metformin treatment on metabolite concentrations, we quantified 131metabolites in fasting serumsamples and usedmultivariable linear regression models in three independent cross-sectional studies (n = 151 patients with T2D treated with metformin [mt-T2D]). Additionally, we used linear mixed-effect models to study the longitudinal KORA samples (n = 912) and performed mediation analyses to investigate the effects of metformin intake on blood lipid profiles. We combined genotyping data with the identified metforminassociated metabolites in KORA individuals (n = 1,809) and explored the underlying pathways. RESULTS We found significantly lower (P < 5.0E-06) concentrations of three metabolites (acyl-alkyl phosphatidylcholines [PCs]) when comparing mt-T2D with four control groupswhowere not using glucose-lowering oralmedication. These findings were controlled for conventional risk factors of T2D and replicated in two independent studies. Furthermore, we observed that the levels of thesemetabolites decreased significantly in patients after they started metformin treatment during 7 years' follow-up. The reduction of these metabolites was also associated with a lowered blood level of LDL cholesterol (LDL-C). Variations of these three metabolites were significantly associated with 17 genes (including FADS1 and FADS2) and controlled by AMPK, a metformin target. CONCLUSIONS Our results indicate that metformin intake activates AMPK and consequently suppresses FADS, which leads to reduced levels of the three acyl-alkyl PCs and LDL-C. Our findings suggest potential beneficial effects of metformin in the prevention of cardiovascular disease.
Original languageEnglish
Pages (from-to)1858-1867
Number of pages10
JournalDiabetes Care
Issue number10
Publication statusPublished - 2015

Cohort Studies

  • Netherlands Twin Register (NTR)


Dive into the research topics of 'Effects of Metformin on Metabolite Profiles and LDL Cholesterol in Patients With Type 2 Diabetes'. Together they form a unique fingerprint.

Cite this